The tumor–stroma ratio and the immune microenvironment improve the prognostic prediction of pancreatic ductal adenocarcinoma
Tóm tắt
Tumor-infiltrating immune cells and fibroblasts are significant components of the tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC), and they participate in tumor progression as closely as tumor cells. However, the relationship between the features of the TME and patient outcomes and the interactions among TME components are still unclear. In this study, we evaluated the PDAC TME in terms of the quantity and location of cluster of differentiation (CD)4+ T cells, CD8+ T cells, macrophages, stromal maturity, and tumor-stroma ratio (TSR), as evaluated by immunohistochemical staining of serial whole-tissue sections from 116 patients with PDAC. The density of T cells and macrophages (mainly activated macrophages) was significantly higher at the invasive margins (IMs) than at the tumor center (TC). CD4+ T cells were significantly association with all the other tumor-associated immune cells (TAIs) including CD8, CD68 and CD206 positive cells. Tumors of the non-mature (intermediate and immature) stroma type harbored significantly more CD8+ T cells at the IMs and more CD68+ macrophages at the IMs and the TC. The density of CD4+, CD8+, and CD206+ cells at the TC; CD206+ cells at the IMs; and tumor-node-metastasis (TNM) staging were independent risk factors for patient outcomes, and the c-index of the risk nomogram for predicting the survival probability based on the TME features and TNM staging was 0.772 (95% confidence interval: 0.713–0.832). PDAC harbored a significantly immunosuppressive TME, of which the IMs were the hot zones for TAIs, while cells at the TC were more predictive of prognosis. Our results indicated that the model based on the features of the TME and TNM staging could predict patient outcomes.
Tài liệu tham khảo
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022 [J]. CA Cancer J Clin. 2022;72(1):7–33.
Harmer M, Denoix P, Hamperl H. Das TNM-System zur Klassifikation von Tumorkrankheiten [J]. Klin Wochenschr. 1968;46(22):1181–5.
Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging [J]. CA Cancer J Clin. 2017;67(2):93–9.
Karamchandani DM, Chetty R, King TS, et al. Challenges with colorectal cancer staging: results of an international study [J]. Mod Pathol. 2020;33(1):153–63.
Athanasakis E, Xenaki S, Venianaki M, et al. Newly recognized extratumoral features of colorectal cancer challenge the current tumor-node-metastasis staging system [J]. Ann Gastroenterol. 2018;31(5):525–34.
Norton J, Foster D, Chinta M, et al. Pancreatic cancer associated fibroblasts (CAF): under-explored target for pancreatic cancer treatment [J]. Cancers. 2020;12(5):1347.
Bolm L, Cigolla S, Wittel UA, et al. The role of fibroblasts in pancreatic cancer: extracellular matrix versus paracrine factors [J]. Transl Oncol. 2017;10(4):578–88.
Santi A, Kugeratski FG, Zanivan S. Cancer associated fibroblasts: the architects of stroma remodeling [J]. Proteomics. 2018;18(5–6): e1700167.
Ozdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival [J]. Cancer Cell. 2014;25(6):719–34.
Rhim Andrew D, Oberstein Paul E, Thomas Dafydd H, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma [J]. Cancer Cell. 2014;25(6):735–47.
Öhlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer [J]. J Exp Med. 2017;214(3):579–96.
Elyada E, Bolisetty M, Laise P, et al. Cross-Species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts [J]. Cancer Discov. 2019;9(8):1102–23.
Knudsen ES, Vail P, Balaji U, et al. Stratification of pancreatic ductal adenocarcinoma: combinatorial genetic, stromal, and immunologic markers [J]. Clin Cancer Res. 2017;23(15):4429–40.
Guerriero JL. Macrophages: their untold story in T Cell activation and function [J]. Int Rev Cell Mol Biol. 2019;342:73–93.
Yang X, Lin J, Wang G, et al. Targeting proliferating tumor-infiltrating macrophages facilitates spatial redistribution of CD8(+) T Cells in pancreatic cancer [J]. Cancers. 2022;14(6):1474.
Carstens JL, Correa De Sampaio P, Yang D, et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer [J]. Nat Commun. 2017;8:15095.
Han S, Fu D, Tushoski GW, et al. Single-cell profiling of microenvironment components by spatial localization in pancreatic ductal adenocarcinoma [J]. Theranostics. 2022;12(11):4980–92.
Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study [J]. Lancet. 2018;391(10135):2128–39.
Huang YK, Wang M, Sun Y, et al. Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry [J]. Nat Commun. 2019;10(1):3928.
Failmezger H, Muralidhar S, Rullan A, et al. Topological Tumor Graphs: A Graph-Based Spatial Model to Infer Stromal Recruitment for Immunosuppression in Melanoma Histology [J]. Cancer Res. 2020;80(5):1199–209.
Fukunaga A, Miyamoto M, Cho Y, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma [J]. Pancreas. 2004;28(1):e26-31.
Wang Z, Zhao J, Zhao H, et al. Infiltrating CD4/CD8 high T cells shows good prognostic impact in pancreatic cancer [J]. Int J Clin Exp Pathol. 2017;10(8):8820–8.
Helm O, Held-Feindt J, Grage-Griebenow E, et al. Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis [J]. Int J Cancer. 2014;135(4):843–61.
Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumors of the digestive system [J]. Histopathology. 2020;76(2):182–8.
Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 [J]. Ann Oncol. 2015;26(2):259–71.
Tahkola K, Leppänen J, Ahtiainen M, et al. Immune cell score in pancreatic cancer-comparison of hotspot and whole-section techniques [J]. Virchows Arch. 2019;474(6):691–9.
Berben L, Wildiers H, Marcelis L, et al. Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software [J]. Histopathology. 2020;77(1):79–91.
Li X, Yuan Y, Ren J, et al. Incremental prognostic value of apparent diffusion coefficient histogram analysis in head and neck squamous cell carcinoma [J]. Acad Radiol. 2018;25(11):1433–8.
Whatcott CJ, Diep CH, Jiang P, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer [J]. Clin Cancer Res. 2015;21(15):3561–8.
Ziani L, Chouaib S, Thiery J. Alteration of the antitumor immune response by cancer-associated fibroblasts [J]. Front Immunol. 2018;9:414.
Roalsø M, Aunan JR, Søreide K. Refined TNM-staging for pancreatic adenocarcinoma—real progress or much ado about nothing? [J]. Eur J Surg Oncol. 2020;46(8):1554–7.
Gok Yavuz B, Gunaydin G, Gedik ME, et al. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1(+) TAMs [J]. Sci Rep. 2019;9(1):3172.
Zhang A, Qian Y, Ye Z, et al. Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma [J]. Cancer Med. 2017;6(2):463–70.
Gorchs L, Fernández Moro C, Bankhead P, et al. Human pancreatic carcinoma-associated fibroblasts promote expression of co-inhibitory markers on CD4(+) and CD8(+) T-Cells [J]. Front Immunol. 2019;10:847.
Ene-Obong A, Clear AJ, Watt J, et al. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma [J]. Gastroenterology. 2013;145(5):1121–32.
Grünwald BT, Devisme A, Andrieux G, et al. Spatially confined sub-tumor microenvironments in pancreatic cancer [J]. Cell. 2021;184(22):5577-5592.e5518.
Lakins MA, Ghorani E, Munir H, et al. Cancer-associated fibroblasts induce antigen-specific deletion of CD8 (+) T Cells to protect tumour cells [J]. Nat Commun. 2018;9(1):948.
Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies [J]. Nat Rev Drug Discov. 2019;18(3):197–218.
Zhang Y, Lazarus J, Steele NG, et al. Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis [J]. Cancer Discov. 2020;10(3):422–39.
Komura T, Sakai Y, Harada K, et al. Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact [J]. Cancer Sci. 2015;106(6):672–86.
Yang Y, Guo Z, Chen W, et al. M2 Macrophage-derived exosomes promote angiogenesis and growth of pancreatic ductal adenocarcinoma by targeting E2F2 [J]. Mol Ther. 2021;29(3):1226–38.
Pelka K, Hofree M, Chen JH, et al. Spatially organized multicellular immune hubs in human colorectal cancer [J]. Cell. 2021;184(18):4734-4752.e4720.
Fu T, Dai LJ, Wu SY, et al. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response [J]. J Hematol Oncol. 2021;14(1):98.
Melzer MK, Arnold F, Stifter K, et al. An immunological glance on pancreatic ductal adenocarcinoma [J]. Int J Mol Sci. 2020;21:9.
Baleeiro RB, Bouwens CJ, Liu P, et al. MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy [J]. Oncoimmunology. 2022;11(1):2080329.
Mi H, Sivagnanam S, Betts CB, et al. Quantitative spatial profiling of immune populations in pancreatic ductal adenocarcinoma reveals tumor microenvironment heterogeneity and prognostic biomarkers[J]. Cancer Res. 2022;82(23):4359–72.
Angell HK, Bruni D, Barrett JC, et al. The immunoscore: colon cancer and beyond[J]. Clin Cancer Res. 2020;26(2):332–9.
Mi H, Gong C, Sulam J, et al. Digital pathology analysis quantifies spatial heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 immune markers in triple-negative breast cancer[J]. Front Physiol. 2020;11: 583333.